Neuland Laboratories Limited (NEULANDLAB)
Healthcare · Pharmaceuticals & Biotechnology · NSE
· Updated 15 July 2026
₹19,114
↑ 25.15% (1Y)
🎯 Key Takeaways
- Revenue grew 28% QoQ to ₹398 in Q3FY25.
Market Cap
₹21,285
P/E Ratio
71.0
Div Yield
0.00%
Promoter
0.0%
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 407 | 363 | 418 | 393 | 385 | 440 | 311 | 398 |
| Operating Profit | 128 | 99 | 141 | 123 | 112 | 149 | 67 | 146 |
| OPM % | 29.4% | 26.7% | 32.9% | 30.9% | 27.8% | 28.1% | 20.0% | 21.8% |
| Net Profit | 85 | 62 | 89 | 81 | 68 | 98 | 33 | 102 |
| EPS | ₹65.90 | ₹48.23 | ₹69.56 | ₹63.44 | ₹52.66 | ₹76.28 | ₹25.60 | ₹79.18 |
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
📋 Recent Filings
-
share transfer 2 July 2026Neuland Laboratories Limited received a SEBI-mandated certificate from its share transfer agent, Kfin Technologies Limited, confirming dematerializati...
-
Financial Results 25 June 2026Neuland Laboratories Limited announced that its trading window will close on July 1, 2026, and remain closed until 48 hours after the quarterly result...
-
Announcement 3 June 2026Neuland Laboratories announced its participation in the Nuvama India Conference 2026 in London on June 8-9, 2026, offering group and one-on-one meetin...
-
Announcement 31 May 2026Neuland Laboratories announced its management will attend a BOFA Healthcare Tour investor meeting in Hyderabad on June 5, 2026, with a note that the s...
-
Announcement 22 May 2026Neuland Laboratories announced its management will attend the 16th Annual Investor Conference hosted by 360 ONE Capital on May 28, 2026 in Mumbai, wit...
-
🔴 Financial Results 16 May 2026Neuland Laboratories reported FY26 revenue of **₹2,053.1 crores**, up 37.1% YoY, with EBITDA margin expanding to 29.4% and PAT reaching **₹363.1 crore...
-
🔴 Corporate Action 12 May 2026Neuland Laboratories reported FY2025-26 audited financials showing revenue of [amount not verified] and net profit of [amount not verified], with a pr...
-
🔴 Financial Results 12 May 2026Neuland Laboratories reported FY26 total income of **₹2053.1 crores** (37.1% YoY growth), with FY26 PAT at **₹363.1 crores** (40% YoY growth) and EBIT...
-
🔴 Financial Results 12 May 2026Neuland Laboratories reported a 134.9% YoY jump in quarterly revenue to Rs. 788.7 crore and a 666.3% YoY surge in net profit to Rs. 212.5 crore for Q4...
-
🔴 Financial Results 12 May 2026Neuland Laboratories reported Q4 FY26 revenue of **₹788.7 crores**, up 134.9% YoY, and net profit of **₹212.5 crores**, up 666.3% YoY, with EBITDA sur...
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.
📡 Get AI alerts when NEULANDLAB files new disclosures
Track NEULANDLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track NEULANDLAB — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research